NHC Submits Comments on MFN Pricing Executive Order
NHC Submits Comments on MFN Pricing Executive Order
Patients Must Be Central to Drug Pricing Reform
The National Health Council (NHC) strongly supports efforts to reduce out-of-pocket costs and improve the affordability of medications for Americans. A core priority of the NHC is ensuring that Americans with chronic diseases and disabilities can access the treatments they need at a cost they can afford. We are increasingly concerned that international trade tariffs and the implementation of a Most Favored Nation (MFN) pricing model could further limit Americans’ access to care, particularly for those on Medicare.
While linking drug prices in the United States to the lowest prices paid in other countries may generate short-term savings, such policies carry significant risks for Americans. These include delays in access to treatments, reduced treatment options, and increased strain on health care providers. Any approach to drug pricing reform must be transparent, focused on sustaining access to high quality, person-centered care, and grounded in patient perspectives.
Patients and their family caregivers are uniquely positioned to identify real-world barriers to care. Their voices must be central in shaping policies that influence how medications are priced, covered, and delivered. The United States should not tie the value of Americans’ treatments to foreign governments with different health care systems and priorities. Instead, we must develop patient-informed solutions that reflect the specific needs of our health care system and the real experiences of the Americans who depend on it.
The NHC remains committed to ensuring that all Americans can access the care they need, including medications, medical devices, health care providers, and specialty care, when they need it.
NHC Submits Comments on MFN Pricing Executive Order
05/12/2025
NHC Submits Comments on MFN Pricing Executive Order
Patients Must Be Central to Drug Pricing Reform
The National Health Council (NHC) strongly supports efforts to reduce out-of-pocket costs and improve the affordability of medications for Americans. A core priority of the NHC is ensuring that Americans with chronic diseases and disabilities can access the treatments they need at a cost they can afford. We are increasingly concerned that international trade tariffs and the implementation of a Most Favored Nation (MFN) pricing model could further limit Americans’ access to care, particularly for those on Medicare.
While linking drug prices in the United States to the lowest prices paid in other countries may generate short-term savings, such policies carry significant risks for Americans. These include delays in access to treatments, reduced treatment options, and increased strain on health care providers. Any approach to drug pricing reform must be transparent, focused on sustaining access to high quality, person-centered care, and grounded in patient perspectives.
Patients and their family caregivers are uniquely positioned to identify real-world barriers to care. Their voices must be central in shaping policies that influence how medications are priced, covered, and delivered. The United States should not tie the value of Americans’ treatments to foreign governments with different health care systems and priorities. Instead, we must develop patient-informed solutions that reflect the specific needs of our health care system and the real experiences of the Americans who depend on it.
The NHC remains committed to ensuring that all Americans can access the care they need, including medications, medical devices, health care providers, and specialty care, when they need it.